Related Experiment Video

Updated: Dec 9, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.9K

The Landscape of CAR-T Cell Clinical Trials against Solid Tumors-A Comprehensive Overview

Niels Schaft1,2,3

  • 1Department of Dermatology, Universtitätsklinikum Erlangen, Friedrich-Alexander-Universität, Erlangen-Nürnberg, Hartmannstraße 14, 91052 Erlangen, Germany.

Cancers
|September 12, 2020
PubMed

Insights

Chimeric antigen receptor T cell (CAR-T) therapy shows promise for blood cancers but struggles with solid tumors. This review analyzes 196 clinical trials to map CAR-T research for solid tumors.

Area of Science:

  • Immunotherapy
  • Oncology
  • Clinical Trials

Background:

  • CAR-T cell therapy has revolutionized hematologic cancer treatment.
  • Significant challenges remain in translating CAR-T efficacy to solid tumors.
  • A comprehensive overview of ongoing CAR-T clinical trials for solid tumors is needed.

Purpose of the Study:

  • To provide a comprehensive overview of the CAR-T cell clinical trial landscape for solid tumors.
  • To analyze geographical distribution, targets, and methodologies of these trials.
  • To report available clinical outcome and safety data.

Main Methods:

  • Systematic review of 196 studies registered on clinicaltrials.gov.
  • Analysis focused on geographical distribution, targeted organs, tumor entities, and antigens.
  • Examination of CAR transfer methods, CAR formats, T cell modifications, patient pretreatment, administration sites, and safety measures.

Main Results:

  • The review details the geographical distribution of CAR-T trials for solid tumors.
  • It identifies targeted organs, tumor entities, and specific antigens being investigated.
  • Information on CAR design, T cell engineering, and clinical trial logistics is presented, alongside limited outcome data.

Conclusions:

  • CAR-T cell therapy for solid tumors is an evolving field with diverse strategies.
  • Understanding the current landscape is crucial for advancing clinical development.
  • Further research and data on clinical outcomes are necessary to overcome challenges.
Keywords:
CAR formatCAR transferCAR-T cellclinical trialclinicaltrials.govsolid tumorsuicide switchtumor antigen

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.1K
Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo05:14

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Published on: July 25, 2025

594

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.4K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
856
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K